Article title: Altered lung metabolism and mitochondrial DAMPs in lung injury due to acute kidney injury Authors: Mark Hepokoski, Jing Wang, Kefeng Li, Ying Li, Purva Gupta, Tina Mai, Alex Moshensky, Mona Alotaibi, Laura E. Crotty Alexander, Atul Malhotra, Prabhleen Singh…
The March 2021 issue of Toxicological Sciences includes exciting toxicology research in biotransformation, toxicokinetics, and pharmacokinetics; genetic and epigenetic toxicology; neurotoxicology; and more.
Article title: Intratubular epithelial-mesenchymal transition and tubular atrophy after kidney injury in mice Authors: Noriyuki Yamashita, Tetsuro Kusaba, Tomohiro Nakata, Aya Tomita, Tomoharu Ida, Noriko Watanabe-Uehara, Kisho Ikeda, Takashi Kitani, Masahiro Uehara, Yuhei Kirita, Satoaki Matoba, Benjamin D. Humphreys, Keiichi Tamagaki From…
A new observational study finds patients in the hospital for COVID-19 have high levels of soluble urokinase receptor (suPAR), an immune-derived pathogenic protein that is strongly predictive of kidney injury.
Article title: T95 nucleophosmin phosphorylation as a novel mediator and marker of regulated cell death in acute kidney injury Authors: Zhiyong Wang, Mostafa Belghasem, Erdjan Salih, Joel Henderson, Chinaemere Igwebuike, Andrea Havasi, Steven C. Borkan From the authors: “In this…
Physician-Scientists and other researchers at Rush University Medical Center, in collaboration with colleagues at other institutions, have revealed a new treatment target that may help change the outcome for patients at risk of AKI.
Study suggests a protein called suPAR could be targeted to prevent dreaded kidney complications in patients undergoing common medical procedures.
High levels of protein in a patient’s urine shortly after an episode of acute kidney injury is associated with increased risk of kidney disease progression, providing a valuable tool in predicting those at highest risk for future loss of kidney function.
In patients taking immune checkpoint inhibitors as a treatment for cancer, 17% experienced acute kidney injury (AKI), 8% experienced sustained AKI, and 3% had potential immune checkpoint inhibitor–related AKI.
• Use of proton pump inhibitors, which are commonly used to treat stomach ulcers or acid reflux, was associated with a higher risk of experiencing sustained AKI.